Pharma Industry Welcomes Duty Waiver on Key Petrochemical Inputs

Industry experts have welcomed the Central government's decision to waive duties on key petrochemical products used in pharmaceuticals and medical devices. The move is aimed at mitigating supply chain disruptions caused by the ongoing conflict in West Asia. Leaders from the pharmaceutical and medical devices sectors state that the waiver on materials like Polypropylene and PVC resin provides critical relief to manufacturers. The simultaneous restoration of RoDTEP export benefits is also praised for enhancing the global competitiveness of Indian medical exports.

Key Points: Duty Waiver on Petrochemicals Eases Pharma Supply Chain

  • Waiver eases medical consumables costs
  • RoDTEP restoration boosts exports
  • Mitigates West Asia conflict supply shocks
  • Ensures uninterrupted medicine supply
3 min read

Experts welcome Centre's decision to waive duties on key petrochemical products

Industry leaders welcome govt's duty waiver on key petrochemicals & RoDTEP restoration to mitigate supply disruptions from West Asia conflict.

"The duty waiver on key petrochemical inputs is a welcome and timely step. - Himanshu Baid"

By Shalini Bhardwaj, New Delhi, April 2

A day after the Central government announced that duties on key petrochemical products will be waived off for enabling timely movement amid the West Asia conflict, industry leaders have welcomed the government's proactive approach to ease the stress of supply-chain disruptions.

The Indian Pharmaceutical Alliance has stated the Centre's decision to waive duties on key petrochemical products.

Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance, said, "The ongoing West Asia conflict is having an impact on energy supplies, freight costs and the timely movement of products. In this difficult situation, we appreciate the Government of India's proactive efforts to mitigate potential supply-related disruptions. The setting up of Empowered Committees of Secretaries, along with continuous review and coordination among all stakeholders, is important."

"The industry also welcomes the restoration of RoDTEP (Remission of Duties and Taxes on Exported Products) to its previous level, as well as the waiver of duty on select products. Our primary focus remains on ensuring the uninterrupted supply of medicines, which is critical to public health and health security", he said further.

Himanshu Baid, Managing Director, Poly Medicure Ltd, welcomed the "timely" step. He said that raw materials, like Polycarbonate, PVC resin and others, which have been exempted, "form the backbone of medical consumables" which will provide a much-needed relief.

"The duty waiver on key petrochemical inputs is a welcome and timely step. The industry expresses its sincere appreciation to the Government of India, especially the Ministry of Finance, Department of Pharmaceuticals and the Ministry of Commerce & Industry for this support. Raw materials such as Polypropylene, ABS, Polycarbonate, and PVC resin form the backbone of medical consumables manufacturing, and their exemption provides much-needed relief to domestic manufacturers, especially MSMEs," he said.

"Additionally, the recent reversal of the earlier 50% reduction in RoDTEP rates is a positive and encouraging move. It will significantly enhance the competitiveness of the Indian medical devices industry on the global stage and support export growth," he added.

Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, also welcomed the step, adding, "The duty waiver on key petrochemical inputs is a positive step for the pharmaceutical sector, as materials such as Polypropylene, Polyethene, PVC and PET form the backbone of pharmaceutical packaging, sterile delivery systems and drug-device combinations. Rationalising input costs supports quality, supply continuity and affordability of medicines."

He further praised the restoration of RoDTEP rates, which he said would strengthen export competitiveness, adding, "The restoration of RoDTEP rates further strengthens export competitiveness and supports India's position as one of the world's most cost-efficient producers of high-quality medicines".

- ANI

Share this article:

Reader Comments

P
Priya S
Good step, but I hope this duty waiver directly translates to lower prices for essential medicines and medical supplies for the common man. The benefit should reach the end consumer.
H
Himanshu A
Proactive governance! The restoration of RoDTEP is crucial. It will help our medical device industry compete globally. 'Make in India' gets a real boost with such timely interventions. 🇮🇳
S
Sarah B
As someone who follows global trade, this is a smart, strategic move. It mitigates external shock from the conflict and secures domestic production. Hope other sectors get similar foresight.
N
Nikhil C
While the intent is good, the execution and monitoring are key. We need to ensure these waivers are not misused and the savings are invested back into quality and R&D, not just pocketed as extra profit.
M
Meera T
This is about health security. Ensuring uninterrupted supply of medicines is non-negotiable. Glad the government and industry are working together on this. A much-needed relief for our pharma sector.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50